Sargent Dorian, Verchère Jérémy, Lazizzera Corinne, Gaillard Damien, Lakhdar Latifa, Streichenberger Nathalie, Morignat Eric, Bétemps Dominique, Baron Thierry
Agence Nationale de Sécurité Sanitaire de l'alimentation, de l'environnement et du travail, Université de Lyon, Lyon, France.
Centre de Pathologie et Neuropathologie Est, Hospices Civils de Lyon, Université de Lyon, Institut Neuromyogène, CNRS, INSERM, Bron, France.
J Neurochem. 2017 Oct;143(1):126-135. doi: 10.1111/jnc.14139. Epub 2017 Sep 5.
The M83 transgenic mouse is a model of human synucleinopathies that develops severe motor impairment correlated with accumulation of the pathological Ser129-phosphorylated α-synuclein (α-syn ) in the brain and spinal cord. M83 disease can be accelerated by intracerebral inoculation of brain extracts from sick M83 mice. This has also recently been described using peripheral routes, injecting recombinant preformed α-syn fibrils into the muscle or the peritoneum. Here, we inoculated homozygous and/or hemizygous M83 neonates via the intraperitoneal and/or intracerebral routes with two different brain extracts: one from sick M83 mice inoculated with brain extract from other sick M83 mice, and the other derived from a human multiple system atrophy source passaged in M83 mice. Detection of α-syn using ELISA and western blot confirmed the disease in mice. The distribution of α-syn in the central nervous system was similar, independently of the inoculum or inoculation route, consistent with previous studies describing M83 disease. ELISA tests revealed higher levels of α-syn in homozygous than in hemizygous sick M83 mice, at least after IC inoculation. Interestingly, the immunoreactivity of α-syn detected by ELISA was significantly lower in M83 mice inoculated with the multiple system atrophy inoculum than in M83 mice inoculated with the M83 inoculum, at the first two passages. 'Prion-like' propagation of the synucleinopathy up to the clinical disease was accelerated by both intracerebral and intraperitoneal inoculations of brain extracts from sick mice. This acceleration, however, depends on the levels of α-syn expression by the mouse and the type of inoculum.
M83转基因小鼠是人类突触核蛋白病的模型,会出现严重的运动障碍,这与大脑和脊髓中病理性的Ser129磷酸化α-突触核蛋白(α-syn)的积累相关。通过脑内接种患病M83小鼠的脑提取物可加速M83疾病的发展。最近也有人描述了通过外周途径,将重组的预形成α-syn原纤维注射到肌肉或腹膜中。在此,我们通过腹腔内和/或脑内途径,用两种不同的脑提取物接种纯合和/或半合子M83新生小鼠:一种来自接种了其他患病M83小鼠脑提取物的患病M83小鼠,另一种来自在M83小鼠中传代的人类多系统萎缩源。使用ELISA和蛋白质印迹法检测α-syn证实了小鼠患有该疾病。α-syn在中枢神经系统中的分布相似,与接种物或接种途径无关,这与之前描述M83疾病的研究一致。ELISA检测显示,至少在脑内接种后,纯合患病M83小鼠中的α-syn水平高于半合子患病M83小鼠。有趣的是,在前两代中,接种多系统萎缩接种物的M83小鼠中通过ELISA检测到的α-syn免疫反应性明显低于接种M83接种物的M83小鼠。通过脑内和腹腔内接种患病小鼠的脑提取物,可加速突触核蛋白病的“朊病毒样”传播直至出现临床疾病。然而,这种加速取决于小鼠α-syn的表达水平和接种物的类型。